Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy of MK-4305 in adults with primary insomnia
2009-015565-31Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Insomnia comparing MK-4305 with Placebo (2 arms). Primary endpoints: Adverse experiences (AEs) and Change from baseline in subjective total sleep time (sTST). Started Oct 2009; status: completed.
02
Drugs
suvorexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on 2009-015565-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015565-31.